Skip to main content
Immunome Inc. logo

Immunome Inc. — Investor Relations & Filings

Ticker · IMNM ISIN · US45257U1088 US Manufacturing
Filings indexed 395 across all filing types
Latest filing 2023-11-28 Regulatory Filings
Country US United States of America
Listing US IMNM

About Immunome Inc.

https://immunome.com/

Immunome Inc. is a clinical-stage oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company specializes in creating first-in-class and best-in-class therapeutic candidates, with a primary focus on Antibody-Drug Conjugates (ADCs) and Radioligand Therapies (RLTs). Immunome utilizes a systematic, data-driven process to optimize each component of its drug candidates—antibody, linker, and payload—to address high unmet medical needs. Its clinical pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand. The company also advances a portfolio of preclinical ADCs targeting various solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-11-28 English
Regulatory Filings 2023
Regulatory Filings
2023-11-22 English
FORM 8-K/A
Regulatory Filings
2023-11-22 English
Regulatory Filings 2023
Regulatory Filings
2023-11-20 English
S-3
Registration Form
2023-11-16 English
FORM 8-K
Regulatory Filings
2023-11-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.